In 10–20% of NSCLC cases, certain carcinogenic mutations (the most common being EGFR aberrations) are present and can be targeted (patients with EGFR mutations are usually treated with tyrosine kinase inhibitors in monotherapy, such as erlotinib [94,95]). This evidence concerns the gene EGFR and non-small cell lung carcinoma.